Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
Status:
Recruiting
Trial end date:
2024-04-16
Target enrollment:
Participant gender:
Summary
Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for
this study. All the eligible patients receive three cycles of induction chemotherapy
(docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two
cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides,
camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the
first day of induction chemotherapy. We aim to evaluate the three years failure free survival
of these patients by the combination of camrelizumab with curative radiotherapy and
chemotherapy.